

eazyplex[®] Candida auris

Avoid ineffective therapy and hygiene management !




- Lyophilized tests
- 5 min sample pretreatment
- No DNA extraction
- Variable device selection
- Real-Time-detection
- **CE IVD**

Direct diagnosis from swab and culture confirmation in 25 min.

„Candida auris poses a risk for patients in healthcare facilities across Europe due to its propensity to cause outbreaks and its antifungal resistance. Difficulties with laboratory identification and lack of awareness of this Candida species may delay early detection increasing the potential for horizontal transmission. C. auris was first identified in 2009 and within a few years has emerged as a cause of healthcare-associated infections. Outbreaks have been reported in countries in five continents. The number of reported C. auris cases in European countries has increased significantly since the last ECDC rapid risk assessment on C. auris in December 2016. There continues to be a need to raise awareness of C. auris in European healthcare facilities, so that they may adapt their laboratory testing strategies and implement enhanced infection prevention and control measures where necessary.

European Centre for Disease Prevention and Control. Candida auris in healthcare settings – Europe – first update, 23 April 2018. Stockholm: ECDC; 2018.

Find out more and contact us under support@eazyplex.com



The **eazyplex[®]** test system is a freeze dried ready to use amplification reaction and can be stored direct at the workplace. During the amplification the result is shown in Real-Time.



AmplexDiagnostics GmbH
Werkstraße 2
83555 Gars Bahnhof
Germany
www.eazyplex.com

Kontakt/Contact

info@eazyplex.com
Tel.: +49 (0) 8073/91693-50
Fax: +49 (0) 8073/91693-55

